José Blanco, MD, discusses whether searching for an accessory spleen or performing accessory splenectomy is a safe and effective treatment for patients with refractory immune cytopenias.
Recent Articles
JAMA Editor-in-Chief Resigns After Releasing Content Questioning Racism in Medicine
In late June, Howard Bauchner, MD, will resign from his role as editor-in-chief of the Journal of the American Medical Association (JAMA) following a...
Will DIY Testing Outlive the COVID-19 Pandemic?
The COVID-19 pandemic has revolutionized diagnostic testing. As the pandemic eases and related restrictions are lifted, public health officials and scientists are looking to...
FDA Approves Pegcetacoplan for Paroxysmal Nocturnal Hemoglobinuria
The U.S. Food and Drug Administration (FDA) has approved the targeted C3 inhibitor pegcetacoplan for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria...
Rusfertide Helps Patients With Polycythemia Vera Avoid Phlebotomy
Patients with polycythemia vera (PV) who received rusfertide were able to avoid therapeutic phlebotomy for seven months, even among those with high-risk disease, according...
Venetoclax Added to Intensive Chemotherapy Is Safe, Effective in Relapsed/Refractory AML
In a study presented at EHA2021 Virtual, the annual congress of the European Hematology Association, adding short-term venetoclax to an intensive FLA-IDA chemotherapy regimen...
Current Issue
June 2021 Volume 7 Issue 7
This issue reviews the management and prevention of peripheral neuropathy, early successes of SCD screening programs in sub-Saharan Africa, and more.